|
Investor
Relations:
Marty
Tullio, Managing Partner
McCloud
Communications, LLC
marty@mccloudcommunications.com
|
|
Delaware
Supreme Court Affirms Chancery Court’s Judgment in Favor of CNS
Response
Costa Mesa,
CA – April 21, 2010 – CNS Response, Inc.
(OTCBB: CNSO) today announced that the Delaware Supreme Court has responded to
the January 4, 2010 filing by the Company’s former CEO, Leonard J.
Brandt, appealing the judgment of the Court of Chancery dated
December 2, 2009. The Delaware Supreme Court affirmed the
Chancery Court’s decision to dismiss with prejudice the complaints brought
against the company by Brandt.
On
December 9, 2009, the Delaware Chancery Court entered judgment for CNS Response
and dismissed with prejudice Brandt’s action brought pursuant to 8 Del. Code
Section 225 finding that a purported special meeting of stockholders convened by
Brandt on September 4, 2009 was not valid and that the directors purportedly
elected at that meeting would not be seated.
The
Chancery Court also denied injunctive relief sought by Brandt to prevent the
voting of shares issued by CNS Response in connection with the Company’s bridge
financing in June and securities offered in August, and dismissed Brandt’s
claims regarding those financings and stock issuances. The Chancery
Court also dismissed with prejudice another action brought by Brandt, in which
he claimed he had not been provided with information owed to him.
About CNS
Response
Today,
most physicians are able to base treatment on objective test data, such as EKGs,
MRIs, blood tests, etc. Broadly speaking, such advances have not yet come to
those physicians practicing psychiatry.
CNS
Response has developed a patented data-analysis capability that, with the help
of a simple, non-invasive EEG, will analyze a patient’s brain waves and compare
the results to an extensive patient outcomes database. The process produces a
rEEG® report providing a psychiatrist with guidance to personalize medication
regimens for a patient, based on the patient's own brain physiology. To
read more about the benefits this patented technology provides physicians,
patients and insurers, please visit the CNS Response website,
www.cnsresponse.com.
# #
#
